CYTK CYTOKINETICS INC
Nasdaq · SEC CIK 1061983 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $52.26M 81 sales by 10 insiders
- Filings on record
- 559 since 2021-07-02, latest 2026-09-22 18:14
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Blum Robert I | Pres, CEO, Dir | — | $17.08M |
| Callos Andrew | EVP, Chief Commercial Off | — | $16.02M |
| Lee Sung | EVP, CFO | — | $5.70M |
| Malik Fady Ibraham | EVP Research, Development | — | $4.65M |
| Kaye Edward M. MD | Dir | — | $3.21M |
| HENDERSON JOHN T | Dir | — | $2.08M |
| WIERENGA WENDELL | Dir | — | $1.88M |
| PARSHALL B LYNNE | Dir | — | $1.36M |
| Landry Robert E | Dir | — | $146.8K |
| Harrington Robert Arthur | Dir | — | $143.6K |
Transactions 784
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-17 | 2026-03-15 | CYTK | Callos Andrew | EVP, Chief Commercial Off | A - Grant | $0.00 | +34.0K | 68.5K | +98% | $0 |
| D | 2026-03-17 | 2026-03-15 | CYTK | Lee Sung | EVP, CFO | A - Grant | $0.00 | +20.6K | 92.1K | +29% | $0 |
| D | 2026-03-17 | 2026-03-15 | CYTK | Malik Fady Ibraham | EVP Research, Development | A - Grant | $0.00 | +27.3K | 165.9K | +20% | $0 |
| D | 2026-03-17 | 2026-03-15 | CYTK | Hessekiel Jeffrey | Chief Legal, Admin Off | A - Grant | $0.00 | +20.6K | 107.9K | +24% | $0 |
| D | 2026-03-17 | 2026-03-15 | CYTK | Blum Robert I | Pres, CEO, Dir | A - Grant | $0.00 | +75.3K | 466.9K | +19% | $0 |
| 2026-03-16 | 2026-03-16 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale | $61.03 | -1,709 | 46.1K | -4% | -$104.3K | |
| 2026-03-10 | 2026-03-09 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $60.72 | -7,931 | 391.7K | -2% | -$481.6K | |
| 2026-03-10 | 2026-03-09 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale | $60.72 | -2,582 | 47.9K | -5% | -$156.8K | |
| 2026-03-10 | 2026-03-09 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale | $60.72 | -2,907 | 138.6K | -2% | -$176.5K | |
| DM | 2026-03-05 | 2026-03-05 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $29.97 | +26.0K | 76.4K | +52% | +$779.3K |
| DM | 2026-03-05 | 2026-03-05 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $61.87 | -26.0K | 61.4K | -30% | -$1.61M |
| 2026-03-02 | 2026-03-02 | CYTK | PARSHALL B LYNNE | Dir | S - Sale | $61.21 | -5,000 | 17.9K | -22% | -$306.1K | |
| D | 2026-03-02 | 2026-03-02 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $61.62 | -886 | 50.4K | -2% | -$54.6K |
| D | 2026-03-02 | 2026-03-02 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $37.63 | +886 | 51.3K | +2% | +$33.3K |
| D | 2026-02-05 | 2026-02-05 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $61.93 | -15.0K | 50.4K | -23% | -$929.0K |
| D | 2026-02-05 | 2026-02-05 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $23.26 | +15.0K | 65.4K | +30% | +$348.9K |
| D | 2026-02-02 | 2026-02-02 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $37.63 | +886 | 51.3K | +2% | +$33.3K |
| D | 2026-02-02 | 2026-02-02 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $62.10 | -886 | 50.4K | -2% | -$55.0K |
| 2026-01-20 | 2026-01-15 | CYTK | Daly James M | Dir | A - Grant | $63.44 | +197 | 197 | New | +$12.5K | |
| 2026-01-16 | 2026-01-15 | CYTK | HENDERSON JOHN T | Dir | A - Grant | $63.44 | +334 | 74.9K | +0.4% | +$21.2K | |
| 2026-01-16 | 2026-01-15 | CYTK | WIERENGA WENDELL | Dir | A - Grant | $63.44 | +98 | 32.5K | +0.3% | +$6,217 | |
| 2026-01-16 | 2026-01-15 | CYTK | Wysenski Nancy | Dir | A - Grant | $63.44 | +98 | 31.0K | +0.3% | +$6,217 | |
| 2026-01-16 | 2026-01-15 | CYTK | Kaye Edward M. MD | Dir | A - Grant | $63.44 | +197 | 10.2K | +2% | +$12.5K | |
| 2026-01-16 | 2026-01-15 | CYTK | Harrington Robert Arthur | Dir | A - Grant | $63.44 | +197 | 18.7K | +1% | +$12.5K | |
| D | 2026-01-05 | 2026-01-05 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $23.26 | +15.0K | 65.4K | +30% | +$348.9K |
| D | 2026-01-05 | 2026-01-05 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $60.28 | -15.0K | 50.4K | -23% | -$904.2K |
| DM | 2026-01-02 | 2026-01-02 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $62.62 | -1,798 | 50.4K | -3% | -$112.6K |
| D | 2026-01-02 | 2026-01-02 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $37.63 | +885 | 51.3K | +2% | +$33.3K |
| 2025-12-30 | 2025-12-29 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale | $62.44 | -1,809 | 51.4K | -3% | -$113.0K | |
| M | 2025-12-29 | 2025-12-22 | CYTK | Callos Andrew | EVP, Chief Commercial Off | A - Grant | $0.00 | +3,177 | 52.2K | +6% | $0 |
| 2025-12-29 | 2025-12-22 | CYTK | Callos Andrew | EVP, Chief Commercial Off | F - Tax | $62.72 | -675 | 53.2K | -1% | -$42.3K | |
| M | 2025-12-29 | 2025-12-22 | CYTK | Lee Sung | EVP, CFO | A - Grant | $0.00 | +4,304 | 72.2K | +6% | $0 |
| 2025-12-29 | 2025-12-22 | CYTK | Lee Sung | EVP, CFO | F - Tax | $62.72 | -805 | 71.4K | -1% | -$50.5K | |
| 2025-12-29 | 2025-12-22 | CYTK | Malik Fady Ibraham | EVP Research, Development | F - Tax | $62.72 | -1,016 | 141.5K | -0.7% | -$63.7K | |
| M | 2025-12-29 | 2025-12-22 | CYTK | Malik Fady Ibraham | EVP Research, Development | A - Grant | $0.00 | +4,000 | 142.6K | +3% | $0 |
| M | 2025-12-29 | 2025-12-22 | CYTK | Blum Robert I | Pres, CEO, Dir | A - Grant | $0.00 | +11.5K | 396.8K | +3% | $0 |
| 2025-12-29 | 2025-12-22 | CYTK | Blum Robert I | Pres, CEO, Dir | F - Tax | $62.72 | -2,935 | 399.6K | -0.7% | -$184.1K | |
| D | 2025-12-23 | 2025-12-22 | CYTK | WIERENGA WENDELL | Dir | S - Sale+OE | $66.14 | -20.0K | 32.4K | -38% | -$1.32M |
| D | 2025-12-23 | 2025-12-22 | CYTK | WIERENGA WENDELL | Dir | M - OptEx | $7.61 | +20.0K | 52.4K | +62% | +$152.2K |
| D | 2025-12-23 | 2025-12-22 | CYTK | Blum Robert I | Pres, CEO, Dir | F - Tax | $68.18 | -30.4K | 374.5K | -8% | -$2.07M |
| DM | 2025-12-23 | 2025-12-22 | CYTK | Blum Robert I | Pres, CEO, Dir | M - OptEx | $6.67 | +71.2K | 391.0K | +22% | +$475.1K |
| D | 2025-12-16 | 2025-12-16 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,200 | 140.8K | +2% | +$23.3K |
| D | 2025-12-16 | 2025-12-16 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $61.24 | -2,200 | 138.6K | -2% | -$134.7K |
| D | 2025-12-08 | 2025-12-08 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $65.96 | -1,042 | 50.7K | -2% | -$68.7K |
| D | 2025-12-08 | 2025-12-08 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $39.13 | +1,042 | 51.7K | +2% | +$40.8K |
| 2025-12-05 | 2025-12-03 | CYTK | Malik Fady Ibraham | EVP Research, Development | F - Tax | $65.02 | -2,058 | 138.6K | -1% | -$133.8K | |
| 2025-12-05 | 2025-12-03 | CYTK | Blum Robert I | Pres, CEO, Dir | F - Tax | $65.02 | -5,930 | 350.2K | -2% | -$385.6K | |
| 2025-12-05 | 2025-12-03 | CYTK | Callos Andrew | EVP, Chief Commercial Off | F - Tax | $65.02 | -1,368 | 50.7K | -3% | -$88.9K | |
| DM | 2025-12-05 | 2025-12-05 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $33.84 | +52.5K | 92.5K | +131% | +$1.78M |
| D | 2025-12-05 | 2025-12-05 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $65.95 | -52.5K | 50.7K | -51% | -$3.46M |
| 2025-12-05 | 2025-12-03 | CYTK | Lee Sung | EVP, CFO | F - Tax | $65.02 | -1,560 | 67.9K | -2% | -$101.4K | |
| D | 2025-12-02 | 2025-12-02 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,200 | 142.8K | +2% | +$23.3K |
| D | 2025-12-02 | 2025-12-02 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $63.89 | -2,200 | 140.6K | -2% | -$140.6K |
| D | 2025-12-02 | 2025-12-02 | CYTK | HENDERSON JOHN T | Dir | M - OptEx | $10.00 | +8,750 | 83.3K | +12% | +$87.5K |
| D | 2025-12-02 | 2025-12-02 | CYTK | HENDERSON JOHN T | Dir | S - Sale+OE | $63.90 | -8,750 | 74.6K | -11% | -$559.1K |
| DM | 2025-12-02 | 2025-12-01 | CYTK | Kaye Edward M. MD | Dir | M - OptEx | $13.72 | +28.1K | 18.0K | New | +$385.0K |
| D | 2025-12-02 | 2025-12-01 | CYTK | Kaye Edward M. MD | Dir | S - Sale+OE | $66.72 | -28.1K | 9,977 | -74% | -$1.87M |
| 2025-12-02 | 2025-12-01 | CYTK | Harrington Robert Arthur | Dir | S - Sale | $66.80 | -2,150 | 18.5K | -10% | -$143.6K | |
| 2025-11-19 | 2025-11-19 | CYTK | PARSHALL B LYNNE | Dir | S - Sale | $64.73 | -5,000 | 22.9K | -18% | -$323.6K | |
| D | 2025-11-18 | 2025-11-18 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,200 | 142.8K | +2% | +$23.3K |
| D | 2025-11-18 | 2025-11-18 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $66.45 | -2,200 | 140.6K | -2% | -$146.2K |
| 2025-11-17 | 2025-11-14 | CYTK | Hessekiel Jeffrey | Chief Legal, Admin Off | A - Grant | $0.00 | +87.3K | 87.3K | New | $0 | |
| D | 2025-11-12 | 2025-11-11 | CYTK | Kaye Edward M. MD | Dir | S - Sale+OE | $65.08 | -5,175 | 9,977 | -34% | -$336.8K |
| D | 2025-11-12 | 2025-11-11 | CYTK | Kaye Edward M. MD | Dir | M - OptEx | $9.66 | +5,175 | 15.2K | +52% | +$50.0K |
| 2025-11-05 | 2025-11-05 | CYTK | Blum Robert I | Pres, CEO, Dir | G - Gift | $0.00 | -2,000 | 356.1K | -0.6% | $0 | |
| D | 2025-11-04 | 2025-11-04 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $59.55 | -2,295 | 140.6K | -2% | -$136.7K |
| D | 2025-11-04 | 2025-11-04 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,295 | 142.9K | +2% | +$24.3K |
| 2025-10-30 | 2025-10-30 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $62.86 | -5,000 | 358.1K | -1% | -$314.3K | |
| D | 2025-10-27 | 2025-10-27 | CYTK | WIERENGA WENDELL | Dir | S - Sale+OE | $58.68 | -4,375 | 32.4K | -12% | -$256.7K |
| D | 2025-10-27 | 2025-10-27 | CYTK | WIERENGA WENDELL | Dir | M - OptEx | $10.00 | +4,375 | 36.8K | +13% | +$43.8K |
| 2025-10-21 | 2025-10-15 | CYTK | WIERENGA WENDELL | Dir | A - Grant | $62.80 | +99 | 32.4K | +0.3% | +$6,217 | |
| D | 2025-10-21 | 2025-10-21 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,105 | 142.7K | +1% | +$22.3K |
| D | 2025-10-21 | 2025-10-21 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $58.22 | -2,105 | 140.6K | -1% | -$122.6K |
| 2025-10-16 | 2025-10-15 | CYTK | HENDERSON JOHN T | Dir | A - Grant | $62.80 | +338 | 74.6K | +0.5% | +$21.2K | |
| 2025-10-16 | 2025-10-15 | CYTK | Wysenski Nancy | Dir | A - Grant | $62.80 | +99 | 30.9K | +0.3% | +$6,217 | |
| 2025-10-16 | 2025-10-15 | CYTK | Kaye Edward M. MD | Dir | A - Grant | $62.80 | +199 | 9,977 | +2% | +$12.5K | |
| 2025-10-16 | 2025-10-16 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $60.03 | -5,000 | 363.1K | -1% | -$300.1K | |
| 2025-10-16 | 2025-10-15 | CYTK | Harrington Robert Arthur | Dir | A - Grant | $62.80 | +199 | 20.7K | +1.0% | +$12.5K | |
| D | 2025-10-07 | 2025-10-07 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $60.56 | -2,000 | 140.6K | -1% | -$121.1K |
| D | 2025-10-07 | 2025-10-07 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.6K | +1% | +$21.2K |
| 2025-10-06 | 2025-10-06 | CYTK | Kaye Edward M. MD | Dir | S - Sale | $60.00 | -6,757 | 9,778 | -41% | -$405.4K | |
| 2025-10-01 | 2025-10-01 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $55.05 | -5,000 | 368.1K | -1% | -$275.2K | |
| 2025-09-30 | 2025-09-30 | CYTK | Kaye Edward M. MD | Dir | S - Sale | $55.08 | -6,695 | 16.5K | -29% | -$368.8K | |
| D | 2025-09-23 | 2025-09-23 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $49.28 | -2,000 | 140.6K | -1% | -$98.6K |
| D | 2025-09-23 | 2025-09-23 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.6K | +1% | +$21.2K |
| 2025-09-15 | 2025-09-15 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $49.77 | -5,000 | 373.1K | -1% | -$248.9K | |
| D | 2025-09-10 | 2025-09-09 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $51.29 | -2,000 | 140.6K | -1% | -$102.6K |
| D | 2025-09-10 | 2025-09-09 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.6K | +1% | +$21.2K |
| 2025-09-02 | 2025-09-02 | CYTK | Harrington Robert Arthur | Dir | S - Sale | $48.67 | -2,150 | 20.5K | -9% | -$104.6K | |
| 2025-09-02 | 2025-09-02 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $48.76 | -5,000 | 378.1K | -1% | -$243.8K | |
| 2025-09-02 | 2025-09-02 | CYTK | Kaye Edward M. MD | Dir | S - Sale | $50.00 | -6,756 | 23.2K | -23% | -$337.8K | |
| D | 2025-08-19 | 2025-08-19 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.6K | +1% | +$21.2K |
| D | 2025-08-19 | 2025-08-19 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $38.31 | -2,000 | 140.6K | -1% | -$76.6K |
| 2025-08-15 | 2025-08-15 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $38.42 | -5,000 | 383.1K | -1% | -$192.1K | |
| D | 2025-08-05 | 2025-08-05 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.6K | +1% | +$21.2K |
| D | 2025-08-05 | 2025-08-05 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $36.34 | -2,000 | 140.6K | -1% | -$72.7K |
| 2025-07-31 | 2025-07-29 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $36.45 | -5,000 | 388.1K | -1% | -$182.2K | |
| D | 2025-07-23 | 2025-07-22 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $37.47 | -2,000 | 140.6K | -1% | -$74.9K |
| D | 2025-07-23 | 2025-07-22 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.6K | +1% | +$21.2K |
| 2025-07-16 | 2025-07-15 | CYTK | Kaye Edward M. MD | Dir | A - Grant | $38.01 | +328 | 30.0K | +1% | +$12.5K |
Purchase Sale Sale after option exercise All abbreviations